Mendus
0.471 SEK -0.84%24 investors are following this company
Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.
P/E (24e)
-3.76
EV/EBIT (adj.) (24e)
-3.22
P/B (24e)
0.72
Dividend yield-% (24e)
-
Target price
0.70 SEK
Recommendation
Accumulate
Updated
10.4.2024
NASDAQ Stockholm
IMMU
Daily low / high price
0.461 / 0.485
SEK
Market cap
473.88M SEK
Turnover
101.52K SEK
Volume
217K
Business risk
Valuation risk
Current
Previous
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Antti Siltanen
Analyst
Latest videos
Financial calendar
General meeting
17.05.2024
Interim report
17.05.2024
Interim report
23.08.2024
Interim report
08.11.2024
Annual report
13.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Adrianus Van Herk | 34.6 % | 34.6 % |
Thomas Eldered | 21.7 % | 21.7 % |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
growth-% | 150.0 % | -60.0 % | 150.0 % | |||||
EBITDA | -86.9 | -132.0 | -138.5 | -133.2 | -123.8 | -123.0 | -93.0 | -95.3 |
EBIT (adj.) | -86.0 | -130.1 | -133.7 | -125.9 | -123.8 | -123.0 | -93.0 | -95.3 |
EBIT | -86.0 | -130.1 | -133.7 | -125.9 | -123.8 | -123.0 | -93.0 | -95.3 |
Profit before taxes | -89.2 | -133.4 | -138.8 | -126.9 | -126.2 | -126.0 | -96.0 | -98.3 |
Net income | -89.2 | -133.4 | -138.8 | -126.9 | -126.2 | -126.0 | -96.0 | -98.3 |
EPS (adj.) | -0.54 | -0.67 | -0.70 | -0.15 | -0.13 | -0.13 | -0.10 | -0.10 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -869,130.0 % | -3,298,775.0 % | -1,385,420.0 % | -1,332,210.0 % | -1,237,780.0 % | -1,229,750.0 % | -930,096.0 % | -953,001.0 % |
EBIT-% (adj.) | -860,270.0 % | -3,252,500.0 % | -1,336,940.0 % | -1,259,210.0 % | -1,237,780.0 % | -1,229,750.0 % | -930,096.0 % | -953,001.0 % |
EBIT-% | -860,270.0 % | -3,252,500.0 % | -1,336,940.0 % | -1,259,210.0 % | -1,237,780.0 % | -1,229,750.0 % | -930,096.0 % | -953,001.0 % |
ROE | -27.2 % | -20.2 % | -23.7 % | -20.8 % | -18.6 % | -21.3 % | -20.0 % | -25.6 % |
ROI | -25.3 % | -19.4 % | -22.3 % | -20.2 % | -18.1 % | -19.7 % | -15.8 % | -16.2 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (SEK) | 6.82 | 3.95 | 2.22 | 0.52 | 0.47 | 0.47 | 0.47 | 0.47 |
Shares | 166.2 | 199.4 | 199.4 | 836.1 | 1,007.2 | 1,007.2 | 1,007.2 | 1,007.2 |
Market cap | 1,132.6 | 787.0 | 442.7 | 437.3 | 473.9 | 473.9 | 473.9 | 473.9 |
Enterprise value | 988.2 | 631.7 | 430.0 | 316.5 | 399.1 | 525.1 | 621.1 | 719.4 |
EV/S | 98,819.4 | 157,933.9 | 43,002.0 | 31,653.6 | 39,913.2 | 52,510.6 | 62,111.6 | 71,941.6 |
EV/EBITDA | - | - | - | - | - | - | - | - |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | 1.7 | 1.2 | 0.9 | 0.6 | 0.7 | 0.9 | 1.1 | 1.4 |
P/S | 113,259.4 | 196,758.9 | 44,267.0 | 43,730.5 | 47,388.3 | 47,388.3 | 47,388.3 | 47,388.3 |
Dividend yield | ||||||||
Equity ratio | 90.7 % | 91.1 % | 82.9 % | 93.2 % | 91.9 % | 82.3 % | 67.4 % | 52.1 % |
Gearing ratio | -21.8 % | -23.6 % | -2.5 % | -17.1 % | -11.4 % | 9.7 % | 34.0 % | 73.5 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | ||||||
EBITDA | -31.2 | -30.2 | -29.0 | -42.7 | -133.2 | -28.6 | -31.0 | -32.0 | -32.3 |
EBIT | -29.6 | -27.7 | -25.9 | -42.7 | -125.9 | -28.6 | -31.0 | -32.0 | -32.3 |
Profit before taxes | -30.2 | -3.3 | -52.2 | -41.2 | -126.9 | -29.2 | -31.6 | -32.6 | -32.9 |
Net income | -30.2 | -3.3 | -52.2 | -41.2 | -126.9 | -29.2 | -31.6 | -32.6 | -32.9 |
ShowingAll content types
Mendus: Changing the course of cancer treatment
Notice of Annual General Meeting in Mendus AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools